Overview

Pemigatinib (Peimeidx) 4.5 mg tablets target a precise molecular driver of bile-duct cancer: the FGFR2 rearrangement that fuels tumor growth in a subset of intrahepatic cholangiocarcinoma. For B2B buyers supporting precision-oncology programs, the mechanism of selective fibroblast growth factor receptor inhibition is the headline differentiator rather than broad cytotoxic activity. This guide walks through how the drug interrupts the FGFR2 signaling axis in molecularly defined disease.

How It Works

Pemigatinib is a potent, selective inhibitor of FGFR1, FGFR2 and FGFR3 that occupies the ATP-binding cleft of the receptor tyrosine kinase. In tumors carrying an FGFR2 fusion or rearrangement, the receptor becomes constitutively active and continuously activates the MAPK and PI3K downstream cascades that promote proliferation. By binding the kinase domain, pemigatinib halts autophosphorylation and shuts off those survival signals, starving the rearranged clone of its growth instruction. The selectivity for FGFR over unrelated kinases is what allows a tolerable, orally delivered targeted approach in a genetically defined patient segment.

Indications

Pemigatinib is indicated for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma whose tumors harbor an FGFR2 fusion or another rearrangement, confirmed by approved testing. Eligibility is therefore tied to biomarker status rather than anatomical stage alone. Procurement teams should plan around companion-diagnostic availability, because the drug delivers value only in the FGFR2-altered population identified through validated molecular profiling.

Dosage & Administration

The product is supplied as 4.5 mg film-coated tablets, 14 tablets per box. Dosing follows a structured cycle with an initial continuous schedule and a planned rest period, adjusted for toxicity. Tablets are swallowed whole with water and may be taken with or without food. Buyers should verify the printed strength and expiry on each blister, since accurate dosing in a narrow-target population depends on receiving the correct 4.5 mg presentation.

Storage & Sourcing

Keep below 30 °C in the original packaging, away from moisture and light; avoid refrigeration. As a targeted agent with a narrow biomarker-defined market, pemigatinib benefits from sourcing through authorized distributors of Incyte and Innovent with full batch documentation. Requests for GMP certificates and certificates of analysis help safeguard authenticity across cross-border oncology supply chains.

FAQ

Q: What makes FGFR2 the relevant target in this cancer? A fusion or rearrangement of FGFR2 locks the receptor in a permanently active state, driving MAPK and PI3K signaling that sustains tumor growth. Pemigatinib blocks that activation at the kinase level.

Q: Is biomarker testing mandatory before treatment? Yes. Confirmed FGFR2 fusion or rearrangement through approved testing is required, because outside that molecular subgroup the drug's rationale disappears.

Q: How should buyers confirm product authenticity? Source from authorized channels, request GMP and analysis certificates, and match batch numbers to manufacturer records before distribution.